PMCF Study of MPS-Flex® Knee System in TKA

Total Knee Arthroplasty Clinical Trial

Official title:

A Multi-Centre Post Market Clinical Follow-Up Study of MPS-Flex® Total Knee Joint Prostheses in Total Knee Arthroplasty

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04427722
• Other study ID #: CSA2019-11K
• Status: Recruiting
• Start date: February 25, 2021
• Est. completion date: December 31, 2032

Study information

• Verified date: October 2022
• Source: Zimmer Biomet
• Contact: Lydia Wang
• Phone: 86-21-2220
• Email: lydia.wang[@]zimmerbiomet.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to obtain implant survivorship and clinical outcomes data for the commercially available MPS-Flex® Total Knee Joint Prostheses used in primary total knee arthroplasty (TKA).

Description:

This is a retrospective and prospective, multi-centre, post-market clinical follow-up study involving orthopedic surgeons skilled in TKA and experienced implanting the devices included in this study. Patient demographic and operative information will be collected retrospectively. Postoperative clinical outcome, radiographic assessment and adverse events will be collected prospectively starting from the first year of postoperative follow up visit.

All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MPS-Flex® Total Knee Joint Prostheses in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: December 31, 2032
• Est. primary completion date: June 30, 2032
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

A patient must meet the following criteria to be eligible for participation:

• Age 18 to 75 years old, inclusive.

• Had a primary unilateral or bilateral (simultaneous or staged)TKA based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:

1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.

2. Collagen disorders and/or avascular necrosis of the femoral condyle.

3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.

4. Moderate valgus, varus, or flexion deformities.

• Had received MPS-Flex® Total Knee Joint Prostheses per the approved indications for use for the TKA.

• Willing and able to provide written informed consent by signing and dating the EC approved informed consent form.

• Willing and able to complete scheduled study procedures and follow-up evaluations.

Exclusion Criteria:

A patient must not meet the following criteria to be eligible for participation:

• The patient is:

1. A prisoner

2. Mentally incompetent or unable to understand what participation in the study entails

3. A known alcohol or drug abuser

4. Anticipated to be non-compliant

• Meet any of the following contraindications of the product.

1. Had previous infection in the operative knee joint, and/or has systemic inflection that could affect prosthesis

2. Insufficient bone stock of tibia or tibia surface

3. Skeleton immaturity

4. Neuropathic arthropathy

5. Osteoporosis, muscle structure or neuromuscular lesions which affects lower limb function

6. The affected joint occurs fusion in the satisfactory functional position and form stable,

7. A history of rheumatoid arthritis with skin ulcers or recurrent skin damage

• Has a diagnosed systemic disease that could affect his/her safety or the study outcome.

• Known sensitivity or allergic reaction to one or more of the implanted materials.

• Known local bone tumors and/or cysts in the operative knee

• Known to be pregnant

• Body Mass Index (BMI) = 40

Related Conditions & MeSH terms

• Total Knee Arthroplasty

Intervention

Device:
• MPS-Flex Total Knee Joint Prostheses
Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.

Locations

Country	Name	City	State
China	Jizhong Erengy Fengfeng Hospital	Handan	Hebei

Sponsors (1)

Lead Sponsor	Collaborator
Zimmer Biomet

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Implant survivorship based on revision	Implant survival will be summarized using a Kaplan-Meier method.	10 years
Secondary	Functional outcome based on Knee Society Score	The Knee Society Scoring System combines an objective physician-derived component with a subjective patient-derived component that evaluates pain relief, functional abilities, satisfaction, and fulfillment of expectations. It consists of four subscales: (1) Objective Knee Score (seven items; 100 points), (2) Satisfaction Score (five items; 40 points), (3) Expectation Score (three items; 15 points), and (4) Functional Activity Score (19 items; 100 points).	10 years
Secondary	Quality of life based on EQ-5D questionnaire	EQ-5D is a standardized measure of health-related quality of life states consisting of 5 dimensions, namely mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L version was used in the study. Each dimension has 5 responses recording 5 levels of severity (no problems/slight problems/moderate problems/severe problems or extreme problems). The responses to the EQ-5D dimensions are used to obtain a single EQ-5D index value where 1 represents full health and 0 represents death. The questionnaire also includes a vertical, visual analogue scale (EQ VAS) for the respondents to record their self-rated health where the 2 extreme ends of the scale are labelled as 'Best imaginable health state' and 'Worst imaginable health state' respectively.	10 years
Secondary	Safety assessment	Summarize the category, incidence and frequency of adverse events	10 years